iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study

Globally, nearly half of patients with type 2 diabetes (T2D) do not successfully achieve target HbA1c with basal insulin, despite meeting fasting plasma glucose (FPG) targets. In this post hoc analysis of the LixiLan‐L study, we determined whether iGlarLixi, a fixed‐ratio combination of insulin glar...

Descripción completa

Detalles Bibliográficos
Autores principales: Morea, Nicola, Retnakaran, Ravi, Vidal, Josep, Aroda, Vanita R., Liu, Minzhi, Saremi, Aramesh, Giorgino, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497103/
https://www.ncbi.nlm.nih.gov/pubmed/32363634
http://dx.doi.org/10.1111/dom.14077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497103/
https://www.ncbi.nlm.nih.gov/pubmed/32363634
http://dx.doi.org/10.1111/dom.14077

Ejemplares similares